Mesenchymal stromal cell-derived membrane particles suppress kidney fibrosis.
Li S., Merino A., Korevaar S., van den Bosch TPP., Baan CC., Reinders MEJ.
Animal Study on Chronic Kidney Disease, Immune Modulation, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Stem Cell Res Ther (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40713899
- DOI
- 10.1186/s13287-025-04522-z
Abstract (original English)
Kidney injury, typically accompanied by inflammation, is a driver for kidney fibrosis, which contributes to the development of kidney failure. Mesenchymal stromal cells (MSC) have been proposed to have anti-fibrotic potential, but challenges such as their short persistence after infusion and inability to cross the lung capillary system due to their large size hamper their use for treatment of kidney fibrosis. It is hypothesized that the effects of MSC are partially dependent on phagocytosis of fragments of MSC by target cells and inhibiting excessive immune activation response. To exploit this effect of MSC, we developed nanosized membrane particles (MP) from MSC and explored their anti-fibrotic activity and immunomodulation effect in mouse and human kidney fibrosis models. MP were generated from culture-expanded MSC through extrusion of isolated membranes. Unilateral kidney ischemia reperfusion injury (IRI) in male Balb/c mice was used to induce kidney fibrosis. MP generated from 1 × 10 6 MSC were injected in the tail vein immediately after anesthesia recovery. In a second model, human induced pluripotent stem cell-derived kidney organoids were exposed to 1% O 2 for 48 h and 100 ng/mL IL-1β for 96 h to mimic IRI in vitro for inducing fibrosis. MP generated from 0.5 × 10 6 MSC were added to the medium for 4 consecutive days. Fibrosis and immune cell markers were subsequently me
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Exosomes in diabetic kidney disease: pathogenesis, biomarker discovery, and emerging therapeutics-a comprehensive systematic review
Systematic Review on Chronic Kidney Disease, published in Ren Fail (2026) — summary generated from the PubMed abstract.
- 2026
Ren Fail - Level AMeta-analysisEurope PMC
Meta-analysis study of the therapeutic impact of Mesenchymal stem cells derived exosomes for chronic kidney diseases
Meta-analysis on Chronic Kidney Disease, published in Biochem Biophys Rep (2025) — summary generated from the PubMed abstract.
- 2025
Biochem Biophys Rep2 citations - Level ASystematic ReviewPubMed
Clinical Safety and Efficacy of Allogeneic Adipose Stem Cells: A Systematic Review of the Clinical Trials.
Systematic Review with a reported sample of 953 on Osteoarthritis, Chronic Kidney Disease, Scar, Autoimmune Research, published in Int J Mol Sci (2025) — summary generated from the PubMed abstract.
- 2025
- n = 953
Int J Mol Sci2 citations - Level ASystematic ReviewEurope PMC
Worldwide hotspots and trends in stem cell therapy for kidney disease in the last decade: a bibliometric and visualization analysis from 2015 to 2024
Systematic Review on Chronic Kidney Disease, Acute Kidney Injury, published in Front Immunol (2025) — summary generated from the PubMed abstract.
- 2025
Front Immunol2 citations - Level AMeta-analysisEurope PMC
Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Meta-analysis on Chronic Kidney Disease, Chronic Inflammation, published in Cells (2025) — summary generated from the PubMed abstract.
- 2025
Cells - Level AMeta-analysisEurope PMC
Protective role of exosomes in renal ischemia-reperfusion injury: a systematic review and meta-analysis
Meta-analysis on Chronic Kidney Disease, Acute Kidney Injury, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol1 citations